A phase I–II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens

By Kosmas Christos   Tsavaris Nicolas   Syrigos Konstantinos   Koutras Angelos   Tsakonas George   Makatsoris Thomas   Mylonakis Nicolas   Karabelis Athanasios   Stathopoulos George   Kalofonos Haralambos  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 51-59

Springer Publishing Company

Access to resources Recommend Favorite

Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: A phase II trial

By Tas Faruk   Demir Cumhur   Camlica Hakan   Ustuner Zeki   Topuz Erkan  

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 233-240

Humana Press, Inc

Access to resources Recommend Favorite

Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

By Koizumi Tomonobu   Yoshiike Fumiaki   Inou Hitoshi   Hatayama Orie   Sasabayashi Mari   Tsushima Kenji   Yamamoto Hiroshi   Hayasaka Muneharu   Kubo Keishi  

Medical Oncology, Vol. 21, Iss. 2, 2004-06 ,pp. : 133-138

Humana Press, Inc

Access to resources Recommend Favorite

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

By  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1133-1133

Oxford University Press

Access to resources Recommend Favorite

Docetaxel: response in patients who have received at least two prior chemotherapy regimes for metastatic breast cancer

By Archer C.D.   Lowdell C.   Sinnett H.D.   English J.   Khan S.   Coombes R.C.  

European Journal of Cancer, Vol. 34, Iss. 6, 1998-05 ,pp. : 816-819

Elsevier

Access to resources Recommend Favorite